SVR Rates Slump With Real-world Use of Sofosbuvir-based HCV Regimens
Key clinical point: The percentage of patients achieving remission was lower in routine clinical practice with sofosbuvir-based regimens than in clinical trials.
Major finding: SVR rates were 66.8% with SOF+PEG+RBV, 75.3% with SOF+SIM, and 74.1% with SOF+SIM+RBV in GT1 patients and 79% with SOF+RBV in GT2 patients.
Data source: An observational, intent-to-treat cohort analysis in 4,026 patients with hepatitis C virus.
Disclosures: Dr. Backus reported having no relevant financial disclosures.
AT DDW 2015
“I think some of it is people have just gotten really spoiled, and we now think that 95% treatment completion is the real world,” she said. “We just don’t see it. I think one may argue that some of the other supposed real world trials, the TARGET or TRIO trials, those generally are people getting seen at academic medical centers. … Those kinds of centers, although they’re a version of the real world, it’s not quite the same as my nurse practitioner in some of the VA clinics.”
